Cargando…
Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis
Pseudomonas infection is a major determinant of morbidity and mortality in cystic fibrosis (CF). Maintaining optimal lung function in CF patients carrying Pseudomonas remains a challenge. Our study aims to investigate the efficacy of antipseudomonal inhaled antibiotics in CF patients with chronic Ps...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388982/ https://www.ncbi.nlm.nih.gov/pubmed/34438986 http://dx.doi.org/10.3390/antibiotics10080936 |
_version_ | 1783742758102499328 |
---|---|
author | Varannai, Orsolya Gede, Noémi Juhász, Márk Félix Szakács, Zsolt Dembrovszky, Fanni Németh, Dávid Hegyi, Péter Párniczky, Andrea |
author_facet | Varannai, Orsolya Gede, Noémi Juhász, Márk Félix Szakács, Zsolt Dembrovszky, Fanni Németh, Dávid Hegyi, Péter Párniczky, Andrea |
author_sort | Varannai, Orsolya |
collection | PubMed |
description | Pseudomonas infection is a major determinant of morbidity and mortality in cystic fibrosis (CF). Maintaining optimal lung function in CF patients carrying Pseudomonas remains a challenge. Our study aims to investigate the efficacy of antipseudomonal inhaled antibiotics in CF patients with chronic Pseudomonas infection. A Bayesian network meta-analysis of randomized controlled trials was conducted. The main outcomes were changes in: (a) forced respiratory volume (FEV1), (b) Pseudomonas aeruginosa sputum density, and (c) CF Questionnaire Revised Respiratory Symptom Score (CFQR-RSS) at 4 weeks follow-up. Eighteen trials which reported on treatment with aztreonam lysine, tobramycin, colistin, levofloxacin, fosfomycin/tobramycin, and amikacin in various dosages were eligible for inclusion. In terms of change in FEV1%, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 77, 76%, respectively). Regarding change in Pseudomonas sputum density, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 90, 86%, respectively). Regarding change in CFQR-RSS, aztreonam lysine (t.i.d., 75 mg) and aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin inhalation solution phase had the highest probability of being the most effective treatments (SUCRA:74% and 72%, respectively). Regarding changes in FEV1% and Pseudomonas sputum density, aztreonam lysine with a run in tobramycin phase may be the best treatment option in treating chronic Pseudomonas in CF. According to CFQR-RSS no significant differences were found. Given the limitations of the studies included, validation trials are called for. |
format | Online Article Text |
id | pubmed-8388982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83889822021-08-27 Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis Varannai, Orsolya Gede, Noémi Juhász, Márk Félix Szakács, Zsolt Dembrovszky, Fanni Németh, Dávid Hegyi, Péter Párniczky, Andrea Antibiotics (Basel) Article Pseudomonas infection is a major determinant of morbidity and mortality in cystic fibrosis (CF). Maintaining optimal lung function in CF patients carrying Pseudomonas remains a challenge. Our study aims to investigate the efficacy of antipseudomonal inhaled antibiotics in CF patients with chronic Pseudomonas infection. A Bayesian network meta-analysis of randomized controlled trials was conducted. The main outcomes were changes in: (a) forced respiratory volume (FEV1), (b) Pseudomonas aeruginosa sputum density, and (c) CF Questionnaire Revised Respiratory Symptom Score (CFQR-RSS) at 4 weeks follow-up. Eighteen trials which reported on treatment with aztreonam lysine, tobramycin, colistin, levofloxacin, fosfomycin/tobramycin, and amikacin in various dosages were eligible for inclusion. In terms of change in FEV1%, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 77, 76%, respectively). Regarding change in Pseudomonas sputum density, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 90, 86%, respectively). Regarding change in CFQR-RSS, aztreonam lysine (t.i.d., 75 mg) and aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin inhalation solution phase had the highest probability of being the most effective treatments (SUCRA:74% and 72%, respectively). Regarding changes in FEV1% and Pseudomonas sputum density, aztreonam lysine with a run in tobramycin phase may be the best treatment option in treating chronic Pseudomonas in CF. According to CFQR-RSS no significant differences were found. Given the limitations of the studies included, validation trials are called for. MDPI 2021-08-03 /pmc/articles/PMC8388982/ /pubmed/34438986 http://dx.doi.org/10.3390/antibiotics10080936 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Varannai, Orsolya Gede, Noémi Juhász, Márk Félix Szakács, Zsolt Dembrovszky, Fanni Németh, Dávid Hegyi, Péter Párniczky, Andrea Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis |
title | Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis |
title_full | Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis |
title_fullStr | Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis |
title_full_unstemmed | Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis |
title_short | Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis |
title_sort | therapeutic approach of chronic pseudomonas infection in cystic fibrosis—a network meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388982/ https://www.ncbi.nlm.nih.gov/pubmed/34438986 http://dx.doi.org/10.3390/antibiotics10080936 |
work_keys_str_mv | AT varannaiorsolya therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis AT gedenoemi therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis AT juhaszmarkfelix therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis AT szakacszsolt therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis AT dembrovszkyfanni therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis AT nemethdavid therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis AT hegyipeter therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis AT parniczkyandrea therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis |